Bayer Aktiengesellschaft (ETR:BAYN) Stock Price Down 1.9% - Here's What Happened

Key Points

• Bayer Aktiengesellschaft shares fell 1.9% on Wednesday to €37.74 (intraday low €36.88) on roughly 3.19 million shares, after closing at €38.47 the prior session.
• The company has a market capitalization of $38.1 billion, a negative P/E (-43.3), high debt-to-equity (144.3), 50‑/200‑day moving averages of €42.55/€34.88, and operates Pharmaceuticals, Consumer Health and Crop Science segments.

Bayer Aktiengesellschaft (ETR:BAYN - ) dropped 1.9% during trading on Wednesday . The company traded as low as €36.88 and last traded at €37.74. Approximately 3,185,697 shares changed hands during trading, The stock had previously closed at €38.47.

Bayer Aktiengesellschaft Trading Down 1.9%

The company has a fifty day moving average of €42.55 and a two-hundred day moving average of €34.88. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 144.30. The stock has a market capitalization of $38.10 billion, a price-to-earnings ratio of -43.30, a price-to-earnings-growth ratio of 36.39 and a beta of 0.93.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.